Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Ernstoff

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Oncotarget|August 7, 2019
Oncologist uptake of comprehensive genomic profile guided targeted therapyMary K Nesline, Paul DePietro, Grace K Dy, et al.
Melanoma Research|February 22, 2023
Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesisIvan P Gorlov, Kathleen Conway, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yangMarc S Ernstoff, Todd S Crocenzi, John D Seigne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patientsThomas Schwaab, Adrian Schwarzer, Benita Wolf, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Oncotarget|August 7, 2019
Oncologist uptake of comprehensive genomic profile guided targeted therapyMary K Nesline, Paul DePietro, Grace K Dy, et al.
Melanoma Research|February 22, 2023
Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesisIvan P Gorlov, Kathleen Conway, Sharon N Edmiston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yangMarc S Ernstoff, Todd S Crocenzi, John D Seigne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2009
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patientsThomas Schwaab, Adrian Schwarzer, Benita Wolf, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
Pageof 17